Author:
Anghelescu Ion-George,Benkert Otto
Publisher
Springer Berlin Heidelberg
Reference34 articles.
1. AlDawsari A, Bushell TJ, Abutheraa N et al (2022) Use of sedative-hypnotic medications and risk of dementia: a systematic review and meta-analysis. Br J Clin Pharmacol 88(4):1567–1589. https://doi.org/10.1111/bcp.15113
2. Appiani FJ, Duarte JM, Sauré M et al (2023) Catatonia and delirium: assessment of comorbidity, prevalence, and therapeutic response in medically ill inpatients from a University Hospital. J Clin Psychopharmacol 43(1):55–59
3. Bandelow B (2020) Current and novel psychopharmacological drugs for anxiety disorders. Adv Exp Med Biol 1191:347–365
4. Bandelow B, Aden I, Alpers GW et al (2021) Deutsche S3-Leitlinie Behandlung von Angststörungen, Version 2. https://register.awmf.org/de/leitlinien/detail/051-028. Zugegriffen: 25. Mai 2023
5. Bedse G, Bluett RJ, Patrick TA et al (2018) Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors. Transl Psychiatry 8(1):92